Massachusetts Patent of the Month – June 2024
Arbor Biotechnologies, Inc. has recently unveiled a groundbreaking advancement in genetic engineering with its engineered CRISPR-Cas systems, specifically designed for enhanced precision and efficiency in modifying nucleic acids within eukaryotic cells. These non-naturally occurring systems harness the power of RNA-guided DNA targeting, revolutionizing the landscape of genome editing.
Unlike conventional CRISPR-Cas systems, Arbor Biotechnologies’ invention integrates a CRISPR-Cas effector protein that binds to a customized RNA guide. This guide includes a direct repeat sequence and a spacer sequence, which can specifically hybridize with target nucleic acids in eukaryotic cells. The engineering prowess of Arbor’s system is highlighted by its ability to modify nucleic acid sequences with unparalleled specificity and effectiveness.
Central to this innovation is the CRISPR-Cas effector protein’s amino acid sequence, meticulously designed and encoded to optimize its binding affinity and enzymatic activity. This precision ensures that the system can induce targeted modifications, such as cleavage or insertion/deletion mutations, in the desired genetic material.
Arbor’s system eliminates the need for a trans-activating RNA (tracrRNA), simplifying the editing process while maintaining robust functionality. This streamlined approach enhances the system’s versatility and adaptability across various genetic manipulation applications.
Arbor Biotechnologies envisions broad applications for its engineered CRISPR-Cas systems in biotechnology, agriculture, and human therapeutics. By providing researchers and developers with a powerful tool for precise genome editing, Arbor aims to accelerate scientific discoveries and therapeutic advancements.
This invention underscores Arbor Biotechnologies’ commitment to pushing the boundaries of genetic engineering, paving the way for transformative innovations that address complex biological challenges and propel scientific progress into the future.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
